Peter Schmid, MD, PhD

Articles

Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC

December 8th 2023

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer. 

Dr. Schmid on Additional Results From the KEYNOTE-522 Trial in Early-Stage TNBC

December 9th 2021

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

Dr. Schmid on Evaluating Biosimilars in Oncology

September 13th 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the evaluation of biosimilars in oncology.

Dr. Schmid on the Role of Biosimilars in Oncology

August 20th 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the role of biosimilars in oncology.

Dr. Schmid on Challenges Concerning Biosimilars in Oncology

May 31st 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses challenges with biosimilars in oncology.

Dr. Schmid on the Design and Findings of the KEYNOTE-173 Trial in TNBC

December 14th 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the phase Ib study of pembrolizumab (Keytruda) in combination with chemotherapy for patients with triple negative breast cancer (TNBC).

Dr. Schmid Discusses the Findings of the IMpassion130 Trial in TNBC

October 23rd 2018

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).